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INTRODUCTION 
Ki67 Labeling Index (Ki67 LI) is currently one of the most promising 
yet controversial biomarker in breast cancer. It has been long 
acknowledged - and more recently several studies have demonstrated - 
that the immunohistochemical (IHC) detection of the Ki67 positive 
tumor cells provides important prognostic information in breast cancer. 
The St. Gallen Consensus Conference in 2015 recommended the use of 
Ki67 LI to distinguish between HER2 negative luminal B-like and 
luminal A-like breast carcinomas. However, the International Ki67 in 
Breast Cancer Working Group is more cautious about the 
recommendation for use of Ki67 in daily practice. The European 
Society for Medical Oncology (ESMO) Clinical Practice Guidelines 
suggests that Ki67 LI may provide useful information, provided the 
assay can be standardized. The American Society of Clinical Oncology 
(ASCO) did not recommend the use of Ki67 LI for prognosis in newly 
diagnosed breast cancer patients because of lack of reproducibility 
across laboratories. 
In addition to ongoing debate on its prognostic utility, Ki67 LI has also 
been investigated as a potential predictive marker for response to 
therapy. In a recent research involving 506 breast cancer patients, Ki67 
LI did not represent an independent predictive potential for neoadjuvant 
chemotherapy. In contrast to this, the systematic review by Luporsi et 
al. has determined a level of evidence of II-B for Ki67 LI regarding 
neoadjuvant treatment response. Despite the promise of Ki67 LI as a 
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prognostic and/or predictive tool, controversy exists regarding its 
applied methodology in practice. Therefore, there is an urgent need for 
reproducible methodology and consistent scoring methods of Ki67 LI. 
To overcome this struggle, the International Ki67 in Breast Cancer 
Working Group has introduced a recommendation for the application of 
Ki67 IHC in daily practice. According to this, parameters that 
predominantly influence the Ki67 IHC results include pre-analytical 
(type of biopsy, tissue handling), analytical (IHC protocol), 
interpretation and scoring, and data analysis steps. Serious efforts have 
been made to improve the pre-analytical and analytical validity of Ki67 
IHC. However, little emphasis had been put so far on a very evident 
technical question, namely, are all commercially available Ki67 
antibodies detecting the same amount of proliferating tumor cells in 
each case? Can we use the different antibodies interchangeably? Most 
published studies concluded that there are indeed differences between 
the protein expression levels detected by different Ki67 antibodies; 
however, to the best of my knowledge, the different results were never 
linked to the prognosis. 
Difficulties in evaluating immunoreactions can also be responsible for 
discrepancies of Ki67 scoring reproducibility. Ki67 LI values are 
usually defined as the percentage of positive tumor cell nuclei, counted 
in 3-10 high-power fields by testing at least 500-1000 tumor cells. 
Another method is to estimate the mean Ki67 LI in the entire lesion. 
Both methods are monotonous, time-consuming and exhausting with a 
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chance of leading to controversial results and inaccurate reproducibility. 
Although the counting method has been recommended by the 
International Ki67 in Breast Cancer Working Group, other studies have 
demonstrated the counting method is not superior to visual estimation. 
Although, recommendations published in 2011 provide a suitable 
landmark to improve pre-analytical and analytical validity, related 
protocols still show high variety and poor reproducibility linked with 
the context of different sampling, fixation, antigen retrieval, staining 
and scoring methods. 
Rapid development of digital microscopy by now allows fast 
digitalization of histological slides at high-resolution, which can firmly 
support education, research and diagnostics in pathology. The 
emergence of digital image analysis (DIA) platforms improved the 
capacity, precision and reproducibility of in situ biomarker evaluation. 
However, these features alone may not be enough for diagnostic 
accuracy, which must be based on histological pattern recognition as 
the most relevant requirement of precise sample selection and 
assessment of immunohistochemical reactions. DIA platforms are able 
to assess Ki67 LI, however it has not been clarified yet, whether their 
results can meet the requirements of the daily diagnostic practice and 
reduce variability of Ki67 scoring. 
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OBJECTIVES 
Three aspects of clinical validity of Ki67 LI are investigated as follows: 
i) The comparison of different Ki67 antibodies used in daily practice. ii) 
The reproducibility between pathologists evaluating Ki67 LI and the 
potential of DIA in Ki67 scoring. iii) The role of Ki67 in neoadjuvant 
setting. Thus, we aimed to: 
1, Compare the semi-quantitatively defined Ki67 LI of five 
commercially available Ki67 IHC antibodies in a consecutive breast 
cancer patient population. 
2, Correlate the prognosis prediction potential of each Ki67 antibodies 
with that of conventional clinicopathological factors in univariate and 
multivariate analyses. 
3, Investigate the reproducibility of Ki67 LI among three pathologists, 
based on their conventional visual estimation. 
4, Test the agreement of semi-quantitative and DIA Ki67 scoring. 
5, Determine and compare the outcome prediction potential of each 
semi-quantitative and DIA assessments with that of conventional 
clinicopathological factors. 
6, Find optimal cut-off values for Ki67 LI in neoadjuvant setting that 
best correlates with response rates to neoadjuvant therapy. 
7, Investigate the association between Ki67 LI, subtype and 
pathological response. 
8, Investigate the prognostic potential of Ki67 LI in neoadjuvant setting 
with multivariate analysis. 
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METHODS 
Two distinct breast cancer patient cohorts were enrolled in the 
investigations encompassing 498 patients totally without any overlap: 
1) 378 consecutive breast cancer cases from the Buda MÁV Hospital 
Pathology Unit, Budapest, Hungary diagnosed between 1999 and 2002 
(ethical approval: TUKEB, #7-1/20)  with 99.80 months median follow 
up (disease-free survival, DFS). 2) 120 patients diagnosed with invasive 
breast cancer and treated with neoadjuvant chemotherapy (NAC) at 
Semmelweis University, Budapest, Hungary between 2002 and 2013 
were retrospectively recruited (ethical approval: TUKEB 120/2013). 
The median follow up time for overall survival (OS) and distant 
metastases-free survival (DMFS) was 60.5 and 59 months, respectively. 
Degree of response to NAC was categorized according to Pinder et al. 
(2007) using the definitions as follows: pathologic complete response 
(pCR), partial response to therapy (pPR), no response to therapy (pNR). 
Regarding the definition of surrogate molecular subtypes of breast 
cancer, we referred to the St. Gallen recommendations from 2013 that 
include five categories (luminal A, luminal B/HER2-, luminal 
B/HER2+, HER2+ and triple negative). 
Tissue microarrays (TMA) were built from 10% neutrally buffered 
FFPE representative tissue blocks of the 378 consecutive cases. 
Duplicate cores (each 2 mm in diameter) were punched (TMA Master, 
3DHISTECH Ltd., Budapest, Hungary) from each case, resulting 10 
TMA blocks. Regarding the neoadjuvant cohort involving 120 cases, 
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the pre-treatment core biopsy specimens and in case of non pCR, the 
surgical specimens were also investigated. 
Paraffin sections of 3 μm thickness were cut from the TMA blocks for 
IHC. The following five antibodies were used for IHC detection of 
Ki67 on TMA blocks: SP6 (Histopathology), 30-9 (Ventana), N1574-
poly (DAKO), B56 (Histopathology), MIB1 (Immunotech). 
Furthermore, Ki67-MIB1 was investigated with immunofluorescent 
labeled (MIB1-IF) antibody (IR 626 DAKO) as well. The IHC reactions 
were performed in an automated immunostainer (Ventana Benchmark 
XT, Roche, Basel, Switzerland) according to the manufacturer’s 
protocol. To detect Ki67 in core biopsy and surgical specimens of the 
neoadjuvant breast cancer cohort MIB1 antibody with chromogen 
detection was used with the same protocol. 
Semi-quantitative (SQ) evaluation of Ki67 IHC of 378 consecutive 
cases was performed on digital slides using the TMA Module software 
on the PannoramicViewer platform as follows: Ki67 LI was defined as 
the percentage of positive tumor cell nuclei, estimated on average in 3-
10 high-power fields, in each core. Any nuclear positivity was 
considered in a range of 100–500 cells, depending on the cellularity of 
the TMA cores. Duplicate cores were evaluated separately and their 
mean Ki67 LI was finally analyzed. 
During the comparison of five Ki67 antibodies, the IHC reactions were 
evaluated by two pathologists independently and if any discrepancy 
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occurred, the inconsistent cases were reassessed and a consensus Ki67 
LI score was given. 
When the reproducibility was investigated between observers, the IHC 
reactions of MIB1 antibody were evaluated by three pathologists (SQ-1, 
SQ-2, SQ-3) independently. The three pathologists have considerable 
but different level of experience in Ki67 scoring of breast cancer. SQ1 
is the youngest with a pathology specialist status for a year only. SQ-2 
and SQ-3 are consultant pathologists with substantial experience in 
diagnostic practice and special focus on breast pathology. Regarding the 
neoadjuvant cohort, the Ki67 IHC reactions were evaluated by two 
pathologists independently and if any discrepancy occurred, the 
inconsistent cases were reassessed and a consensus Ki67 LI score was 
given. 
TMA slides were digitized with Pannoramic Flash II slide scanner using 
x20 objective (NA=0.83). DIA was performed on the IHC reactions of 
MIB1 antibody using the PatternQuant (PQ) software enabling 
automated tissue pattern recognition by separating epithelial elements 
from stroma. All digital hardware and software tools were from 
3DHISTECH Ltd. (Budapest, Hungary). Designation of training tissue 
patterns to be recognized and the calibration were done in co-operation 
by a pathologist and an IT expert to achieve the best recognition pattern 
(achieved at a PQ training magnification of 1.5x; a gamma level of 1; 
dilution of 3; a contour of 0). So, as the detection and quantification of 
tumor cell nuclei using NuclearQuant (NQ) at the following settings: 
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Blur: 15; Radius minimum: 1.5; Radius maximum: 8; Area min: 15; 
Intensity minimum: 30; Contrast minimum 30. Based on these settings 
of PQ and NQ, automated Ki67 evaluation was performed on each core 
(DIA-1 analysis). In the other DIA test, automated annotations were 
assessed by pathologists on each core, and when it was necessary, DIA 
settings were adjusted independently to exclude artifacts, 
underestimation or overestimation of positive/negative cells and false 
detections (DIA-2 analysis). 
Degree of agreement among different antibodies detecting Ki67 and the 
reproducibility between Ki67 evaluations  was evaluated by using intra-
class correlation coefficient (ICC), concordance correlation coefficient 
(CCC), Cohen's kappa and Bland-Altman plot (MedCalc 13.3.3.0, 
Ostend, Belgium). To assess statistical differences between each 
antibody and between observers, Wilcoxon signed-rank and McNemar 
tests were applied, since our data were not normally-distributed, even 
after log-transformation (Shapiro-Wilk and Kolmogorov-Smirnov 
tests). The optimal cut-off value for Ki67 percentage to discriminate 
response to treatment was assessed by receiver operating characteristic 
(ROC) curve analysis. To identify the optimal Ki67 threshold for NAC, 
only pCR and pNR cases were involved in ROC analyses, because pPR 
status is considered as a soft endpoint. Kaplan-Meier analysis supported 
with log-rank test and multivariate Cox-regression was executed to 
assess prognostic potential (SPSS 22 software, IBM, Armonk, USA). In 
all statistical analysis, the level of significance was set at p< 0.05. 
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RESULTS 
The validity of five Ki67 antibodies 
The Ki67 LI scores of the 5 antibodies showed a moderate agreement. 
Highest concordance was observed between MIB1 and poly, 30-9 and 
poly, MIB1 and B56, 30-9 and SP6 as well as between MIB1 and 30-9. 
Conversely, lowest agreement was found between SP6 and B56 as well 
as between SP6 and MIB1-IF. Significant bias was observed in all 
comparisons except MIB1 vs. MIB1-IF and the range of agreement was 
also wide. Furthermore, a systematic error was found between all the 
antibodies except between MIB1 and poly. For prognosis, all the Ki67 
antibodies but the IF detection of MIB1 could perform statistically 
significant splitting of our cohort into 2 patients’ groups with distinct 
DFS at 20% threshold. At 30% cut-off point, Ki67 LI of MIB1, SP6, 
30-9 and poly could distinguish good and unfavorable prognosis 
patients’ cohorts. Meanwhile B56 and MIB1-IF did not represent any 
statistically significant prognosis predictor potential at 30% threshold. 
We had also investigated the utility of each Ki67 antibodies as potential 
independent predictors of DFS adjusted by age, IHC subtypes, lymph 
node and T status, histological grade, mitotic index, vascular invasion 
as well as necrosis at 20% and 30% thresholds. At 20% cut-off score, 
Ki67 LI of poly and lymph node status were significantly linked to DFS 
However, at 30% threshold, only lymph node status represented an 
independent association with survival. 
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The reproducibility between different Ki67 evaluations 
Since MIB1 is the most widely used antibody to detect Ki67 LI and 
showed the highest concordance and agreement with the poly antibody, 
it was used in the further investigations. 
The 3 SQ Ki67 LI assessments showed a very good consistency 
concerning the relative difference between cases. The best interobserver 
variability was found between SQ-2 and SQ-3 while SQ-1 showed poor 
concordance with SQ-2 and SQ-3. Significant bias was observed in all 
comparisons. The lowest bias and the narrowest range of agreement 
were found between SQ-2 and SQ-3 without a systematic error. Upon 
dichotomizing Ki67 LI values at 14% and 20% thresholds, SQ-1 still 
differed considerably from SQ-2 and SQ-3 with a moderate agreement. 
However, no significant difference, and substantial agreement were 
found between SQ-2 and SQ-3, at these thresholds.For the comparison 
with DIA assessments, a reference SQ Ki67 LI value was generated 
(SQ-RV) as the mean of SQ-2 and SQ-3, since SQ-1 differed 
considerably from those. SQ-RV and automated DIA-1 differed and 
showed moderate concordance. SQ-RV and adjustable DIA-2 showed 
no significant difference, and represented a substantial concordance. 
Significant difference but substantial concordance was found when 
DIA-1 was compared to DIA-2. A significant bias and proportional 
error was found between SQ-RV and DIA-1 values, which was not seen 
between SQ-RV and DIA-2 values and the range of agreement was also 
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superior in the latter case. For prognosis, all Ki67 evaluations but SQ-3 
could perform statistically significant splitting of our cohort into 2 
patients’ group with distinct DFS at 14% threshold. At 20% cut-off 
point, Ki67 evaluations of DIA-2, SQ-2 andSQ-3 could sort patients 
into good and unfavorable prognostic groups, while SQ-1 and DIA-1 
did not. Ki67 LI assessments were also tested as potential independent 
predictors of DFS adjusted by age, IHC subtypes, lymph node and T 
status, histological grade, mitotic index, vascular invasion as well as 
necrosis. At 14% cut-off, no Ki67 LI evaluation but only lymph node 
status showed independent association with DFS. However, at 20% 
threshold, both lymph node status and SQ-2 were significantly linked to 
DFS. 
The role of Ki67 in neoadjuvant setting 
The optimal Ki67 LI cut-off value was 20% for distinguishing pCR 
from pNR patient cases. Pathological response and Ki67 LI at 
investigated thresholds represented a significant association. The 
proportion of Ki67 LI low cases among non-responders was 
significantly higher compared to pPR and pCR cases. The distribution 
of subtypes showed a significant difference in pathological response 
groups. Most of the TNBC cases were represented in pCR group, while 
luminal A cases mainly occurred in pPR and pNR groups. The Ki67 
expression at any investigated cut-off points and subtypes also 
represented a significant correlation. Luminal A subtype showed low 
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Ki67 LI, while TNBC and HER2+ cases mostly had high Ki67 LI. The 
association between Ki67 LI, subtype and pathological response was 
also investigated without luminal A cases, because NAC is not 
generally recommended in this subtype due to the high rate of pNR in 
contrast with the favorable prognosis. Excluding luminal A cases, Ki67 
LI at any thresholds and pathological response did not show any 
significant association. Furthermore, Ki67 LI at any investigated cut-off 
points also did not represent any significant linkage with subtypes. In 
contrast to this, subtypes were significantly linked to the pathological 
response groups. The clear majority of luminal B cases were in pPR and 
pNR groups, while TNBC cases mostly occurred in pCR subgroup. 
Regarding OS, Ki67 LI at 15% and at 20% threshold failed, but Ki67 LI 
at 30% cut-off value, furthermore subtype as well as pathological 
response were suitable to separate patients into good and unfavorable 
prognosis cohorts. When luminal A cases were excluded, neither Ki67 
LI at any cut-off points nor subtype not even pathological response 
were suitable to perform statistically significant splitting of our cohort 
into 2 patients’ group with different OS. We also investigated the utility 
of Ki67 LI at 15%, 20% and 30% thresholds as potential independent 
predictor of OS adjusted by age, pathological response, hormone 
receptor status, subtypes, histological grade, lymph node, cT and pT 
status. Ki67 LI at 30% threshold and subtype were independently linked 
to OS. Without luminal A cases, Ki67 LI at 30% cut-off point and 
subtype represented also an independent association with OS. 
13 
 
CONCLUSIONS 
In surgical pathology practice, the selection and then the validation of 
Ki67 antibody requires great caution. Our results suggest that, as MIB1, 
poly, 30-9 antibodies showed the highest performance, they are suitable 
to detect Ki67 expression in the daily practice. We believe that this 
study provides a partial explanation to the various suggested Ki67 LI 
cut-off values in different published series of breast cancer cases. 
The pathologists’ experience is essential to control and adjust DIA and 
to avoid false detections. We also demonstrate that the adjustable DIA 
can be a feasible and reproducible tool to evaluate Ki67 LI in breast 
cancer which may support standardization efforts. 
Neoadjuvant chemotherapy is more efficient in tumors presenting at 
least 20% Ki67 LI. A cut-off value of 20% distinguished pCR from 
pNR cases. Increased Ki67 LI was linked to worse OS, meaning that at 
least in some subgroups higher Ki67 expression is related to increased 
response to NAC and is also associated with worse prognosis. 
Additionally, our data also suggest that if a tumor is non-responder to 
NAC, increased Ki67 LI is a poor prognostic marker. Moreover, we 
provide further evidence that Ki67 LI is a significant and independent 
prognostic marker in breast cancer. Thus, we can conclude that Ki67 
has potential utility in the clinical management of breast cancer. 
However, we can also state that Ki67 LI in itself is not suitable to 
decide whether a breast cancer patient should be treated with NAC or 
not. 
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